SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Titan Pharmaceuticals (TTNP)

Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator interstate, TRUTH, matthewverymuch, Ppower
Search This Board:
Last Post: 8/4/2015 2:20:28 PM - Followers: 164 - Board type: Free - Posts Today: 4



Probuphine®-This study is enrolling participants by invitation only.

Click For Link To

*November 20, 2014 -  the study is 100% enrolled. 
   * First patients enrolled on Jul 21, 2014 *                                  * DrKate Glassman-Beebe- Executive Vice President and Chief Development Officer-Titan Pharmaceuticals

Click For Link 


Braeburn Pharmaceuticals Identifier:
Information provided by (Responsible Party):
First received: July 1, 2014
Last updated: July 8, 2014
Last verified: July 2014
Braeburn Pharmaceuticals

Probuphine Graphic




Continuous Drug Delivery Technology


The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.


Fanapt® (iloperidone)


Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.

Company Overview

Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.


Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.


The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] quotations system. For further information please contact


Management Team

Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.


Board of Directors



Strategic Alliances

In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.


Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TTNP News: Proxy Statement (definitive) (def 14a) 07/20/2015 06:02:19 AM
TTNP News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 06/26/2015 03:40:43 PM
TTNP News: Current Report Filing (8-k) 06/15/2015 08:25:22 AM
TTNP News: Current Report Filing (8-k) 06/09/2015 06:05:25 AM
TTNP News: Quarterly Report (10-q) 05/13/2015 02:47:57 PM
#5431  Sticky Note From brae's website... matthewverymuch 06/08/15 08:17:08 AM
#5818   My guess is you will see no news interstate 08/04/15 02:20:28 PM
#5817   Braeburn still has the "help wanted" ad up matthewverymuch 08/04/15 01:34:02 PM
#5816   We are seeing how that lipstick turks 08/04/15 01:32:50 PM
#5815   Yep. Garbage. Wonder what sunil and rubin and matthewverymuch 08/04/15 01:03:32 PM
#5814   Matt,couldn't of said it better.One big heap turks 08/03/15 07:21:29 PM
#5813   Let the garbage volume and garbage trading continue.. matthewverymuch 08/03/15 02:35:16 PM
#5812   They're not going to inform shareholders of the TRUTH 08/01/15 02:20:53 PM
#5811   If the reverse split is approved. interstate 08/01/15 10:09:38 AM
#5810   According to yahoo his pay is $300k+(that his Rentier 07/31/15 04:58:40 PM
#5809   How much insider buying would satisfy you exactly? matthewverymuch 07/31/15 02:37:23 PM
#5808   As for the upcoming penalty, TOO BAD. Shouldn't TRUTH 07/31/15 01:38:38 PM
#5807   Their whole goal is to yet again dump Rentier 07/31/15 01:28:35 PM
#5805   Truth your right,if they where to provide a turks 07/31/15 09:29:43 AM
#5804   Good! Let them find a way to get matthewverymuch 07/30/15 05:35:57 AM
#5803   ,they really don't need to dilute TRUTH 07/29/15 10:52:37 PM
#5802   Hi truth,I am sure maybe turks 07/29/15 10:42:13 PM
#5801   Oh, well guess Braeburn better step up and Rentier 07/29/15 06:38:45 PM
#5800   Well Rentier, TRUTH 07/29/15 06:08:48 PM
#5799   If you vote no to the RS... the interstate 07/29/15 04:42:19 PM
#5798   They will just sell more shares diluting what Rentier 07/28/15 08:38:04 PM
#5797   Seems no one is willing to pay more matthewverymuch 07/28/15 02:51:22 PM
#5796   Yes. Haven't yet voted, though. matthewverymuch 07/28/15 02:48:50 PM
#5795   Did you receive your proxy forms via your TRUTH 07/28/15 02:46:53 PM
#5794   Nevermind. I don't think these guys have the matthewverymuch 07/28/15 11:07:22 AM
#5793   What is the implication of that? shadolane 07/27/15 02:30:19 PM
#5791   With the pps still falling maybe a 1:8 shadolane 07/27/15 10:34:00 AM
#5790   I hope you are right. shadolane 07/27/15 10:30:10 AM
#5789   These guys ain't exactly top flight talent at matthewverymuch 07/27/15 09:39:46 AM
#5788   I agree with what you say. shadolane 07/27/15 08:58:06 AM
#5787   I have been doing some more thinking about interstate 07/27/15 08:42:56 AM
#5786   The only thing I do not with the interstate 07/23/15 01:53:35 PM
#5785   Ttnp finished up today by a little......very little. Chia 07/22/15 11:30:07 PM
#5784   They repeatedly lie and mislead, heck a CC Rentier 07/22/15 06:49:49 PM
#5783   Ummmm... the statement imply that they have recently interstate 07/21/15 09:09:52 AM
#5782   10 Things To Know About Prescription Opioid Abuse TRUTH 07/21/15 06:23:23 AM
#5781   Even though I have stated that I am Chia 07/20/15 10:50:59 PM
#5780   I am sure then have been in 'talks' Rentier 07/20/15 08:37:24 PM
#5779   I like this part of the proxy. interstate 07/20/15 12:54:11 PM
#5777   I never believed in the theories of shorts TRUTH 07/19/15 01:15:45 AM
#5776   I never believed in the theories of shorts Chia 07/18/15 11:21:25 PM
#5775   Roth Ups Titan Pharma Price Target To $1.50 TRUTH 07/18/15 12:48:39 PM
#5774   Has to be before,after we should be trading turks 07/17/15 09:00:01 PM
#5773   .is it 1.5 before approval or after? TRUTH 07/17/15 07:46:45 PM
#5772   You are it 1.5 before approval or after? matthewverymuch 07/17/15 06:32:52 PM
#5771   Thanks mvm.... TRUTH 07/17/15 05:10:43 PM
#5770   I still remember their January 26th 2015 Article: TRUTH 07/17/15 03:32:26 PM
#5769   Could be this.. matthewverymuch 07/17/15 03:25:59 PM
#5768   .looks like another buy the rumor, sell the TRUTH 07/17/15 03:24:34 PM